PEG conjugated VEGF siRNA for anti-angiogenic gene therapy

Cited 235 time in webofscience Cited 0 time in scopus
  • Hit : 536
  • Download : 65
DC FieldValueLanguage
dc.contributor.authorKim, Sun-Hwako
dc.contributor.authorJeong, Ji-Hoonko
dc.contributor.authorLee, Soo-Hyeonko
dc.contributor.authorKim, Sung-Wanko
dc.contributor.authorPark, Tae-Gwanko
dc.date.accessioned2009-11-10T05:27:17Z-
dc.date.available2009-11-10T05:27:17Z-
dc.date.created2012-02-06-
dc.date.created2012-02-06-
dc.date.issued2006-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, v.116, no.2, pp.123 - 129-
dc.identifier.issn0168-3659-
dc.identifier.urihttp://hdl.handle.net/10203/12345-
dc.description.abstractfA novel siRNA delivery system based on polyelectrolyte complex (PEC) micelles was introduced in this study. Vascular endothelial growth factor (VEGF) siRNA was conjugated to poly(ethylene glycol) (PEG) via a disulfide linkage (siRNA-PEG). The siRNA-PEG conjugate could form PEC micelles by interacting with cationic polyethylenimine (PEI) as a core forming agent. The VEGF siRNA-PEG/PEI PEC micelles showed greater stability than naked VEGF siRNA against enzymatic degradation. Under a reductive condition similar to cytosolic environment, an intact form of siRNA was released from the siRNA-PEG conjugate by cleavage of the disulfide linkage. The VEGF siRNA-PEG/PEI PEC micelles effectively silenced VEGF gene expression in prostate carcinoma cells (PC-3) up to 96.5% under an optimized formulation condition. They also showed a far superior VEGF gene silencing effect than VEGF siRNA/PEI complexes even in the presence of serum. This study suggests that the siRNA delivery system using VEGF siRNA-PEG/PEI PEC micelles could be potentially applied to RNAi-based anti-angiogenic treatment of cancer in vivo. (c) 2006 Elsevier B.V. All rights reserved.-
dc.description.sponsorshipthe Ministry of Science and Technology (M10414030002-05N1403-00210), Korea and from the National Institute of Health (CA107070), USA.en
dc.languageEnglish-
dc.language.isoen_USen
dc.publisherElsevier Science Bv-
dc.subjectENDOTHELIAL GROWTH-FACTOR-
dc.subjectPOLYELECTROLYTE COMPLEX MICELLES-
dc.subjectSMALL INTERFERING RNA-
dc.subjectIN-VIVO-
dc.subjectCHEMICAL-MODIFICATIONS-
dc.subjectPOLYETHYLENE-GLYCOL-
dc.subjectMAMMALIAN-CELLS-
dc.subjectCANCER-
dc.subjectDELIVERY-
dc.subjectTHERAPEUTICS-
dc.titlePEG conjugated VEGF siRNA for anti-angiogenic gene therapy-
dc.typeArticle-
dc.identifier.wosid000245332000004-
dc.identifier.scopusid2-s2.0-33845216721-
dc.type.rimsART-
dc.citation.volume116-
dc.citation.issue2-
dc.citation.beginningpage123-
dc.citation.endingpage129-
dc.citation.publicationnameJOURNAL OF CONTROLLED RELEASE-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.contributor.localauthorPark, Tae-Gwan-
dc.contributor.nonIdAuthorKim, Sun-Hwa-
dc.contributor.nonIdAuthorJeong, Ji-Hoon-
dc.contributor.nonIdAuthorKim, Sung-Wan-
dc.type.journalArticleArticle; Proceedings Paper-
dc.subject.keywordAuthorgene delivery-
dc.subject.keywordAuthorvascular endothelial growth factor-
dc.subject.keywordAuthorsiRNA-PEG conjugate-
dc.subject.keywordAuthorpolyelectrolyte complex micelles-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusPOLYELECTROLYTE COMPLEX MICELLES-
dc.subject.keywordPlusSMALL INTERFERING RNA-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCHEMICAL-MODIFICATIONS-
dc.subject.keywordPlusPOLYETHYLENE-GLYCOL-
dc.subject.keywordPlusMAMMALIAN-CELLS-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordPlusTHERAPEUTICS-
Appears in Collection
BS-Journal Papers(저널논문)
Files in This Item
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 235 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0